Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jun 3;14(1):12685.
doi: 10.1038/s41598-024-63443-8.

Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial

Affiliations
Randomized Controlled Trial

Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: a 12-week, double-blind, placebo-controlled, randomized trial

Ralf Jäger et al. Sci Rep. .

Abstract

White kidney bean (Phaseolus vulgaris L.) extracts can aid weight management by reducing calorie intake from complex carbohydrates through alpha-amylase inhibition. We examined the impact of a proprietary aqueous extract from whole dried white kidney beans standardized by its alpha-amylase inhibitor activity (Phase 2 white kidney bean extract (WKBE)) on weight management in subjects with overweight and moderate obesity. In a randomized, double-blind, placebo-controlled fashion, 81 participants completed the study and ingested either a high dose of Phase 2 (1000 mg, WKBE HIGH), a low dose (700 mg, WKBE LOW), or a matching placebo (microcrystalline cellulose, PLA) three times a day, 30 min before meals, for 12 weeks during a calorie restricted diet. In a dose-dependent manner, Phase 2 significantly reduced body weight, fat mass, BMI, waist, hip and in the WKBE HIGH group thigh circumference. Phase 2 is an effective and safe supplement aiding weight and fat loss. ClinicalTrials.gov identifier NCT02930668.

Keywords: BMI; Body shaping; Fat mass; Obesity; Weight management.

PubMed Disclaimer

Conflict of interest statement

Drs. Jäger and Purpura are consultants to Ashland, the manufacturer of Phase 2. All other authors do not declare any competing interests.

Figures

Figure 1
Figure 1
CONSORT Flow Diagram.
Figure 2
Figure 2
Changes in body weight at (A) 4 weeks (B) 8 weeks and (C) 12 weeks in response to supplementation with white kidney bean extract. *WKBE significantly different than PLA (p < 0.001). Means ± SD.
Figure 3
Figure 3
Changes in BMI at (A) 4 weeks (B) 8 weeks and (C) 12 weeks in response to supplementation with white kidney bean extract. *WKBE significantly different than PLA (p < 0.001). Means ± SD.
Figure 4
Figure 4
Changes in fat mass at (A) 4 weeks (B) 8 weeks and (C) 12 weeks and fat free mass at (D) 4 weeks (E) 8 weeks and (F) 12 weeks in response to supplementation with white kidney bean extract. *WKBE groups significantly different than PLA (p < 0.05). Means ± SD.
Figure 5
Figure 5
The proportion of participants who lost at least 3% of body weight at (A) 4 weeks (B) 8 weeks and (C) 12 weeks and 5% of body weight at (D) 4 weeks (E) 8 weeks and (F) 12 weeks in response to supplementation with white kidney bean extract. †WKBE HIGH significantly different than WKBE LOW. *WKBE groups significantly different than PLA (p < 0.05)..
Figure 6
Figure 6
Changes in waist circumference at (A) 4 weeks (B) 8 weeks and (C) 12 weeks, hip circumference at (D) 4 weeks (E) 8 weeks and (F) 12 weeks and thigh circumference at (G) 4 weeks (H) 8 weeks and (I) 12 weeks in response to supplementation of white kidney bean extract. †WKBE HIGH different than WKBE LOW. *WKBE groups significantly different than PLA (p < 0.05). Means ± SD.

References

    1. World Health Organization, Obesity and overweight. 1 March 2024. www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 30 April 2024.
    1. Witkos M, Uttaburanont M, Lang CD, Arora R. Costs of and reasons for obesity. J. Cardiometab. Syndr. 2008 doi: 10.1111/j.1559-4572.2008.00012.x. - DOI - PubMed
    1. Bray GA. Obesity increases risk for diabetes. Int. J. Obes. Relat. Metab. Disord. 1992;16(Suppl 4):S13–S17. - PubMed
    1. Tanaka M. Improving obesity and blood pressure. Hypertens Res. 1992 doi: 10.1038/s41440-019-0348-x. - DOI - PubMed
    1. Alexander JK. Obesity and coronary heart disease. Am. J. Med. Sci. 2001 doi: 10.1097/00000441-200104000-00002. - DOI - PubMed

Publication types

Associated data